Envista (NVST)
(Delayed Data from NYSE)
$20.02 USD
-0.26 (-1.28%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $20.02 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Envista (NVST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$25.55 | $33.00 | $18.00 | 25.99% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Envista comes to $25.55. The forecasts range from a low of $18.00 to a high of $33.00. The average price target represents an increase of 25.99% from the last closing price of $20.28.
Analyst Price Targets (11)
Broker Rating
Envista currently has an average brokerage recommendation (ABR) of 2.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 2.67 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, four are Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 6 | 6 | 6 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 1 |
ABR | 2.67 | 2.67 | 2.67 | 2.67 | 2.09 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/26/2024 | SVB Securities | Michael Cherny | Not Available | Strong Sell |
2/8/2024 | William Blair | Brandon Vazquez | Strong Buy | Hold |
2/8/2024 | Piper Sandler | Jason Bednar | Hold | Hold |
11/16/2023 | Needham & Company | David Saxon | Not Available | Hold |
10/5/2023 | Robert W. Baird & Co. | Jeffrey D Johnson | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.67 |
ABR (Last week) | 2.67 |
# of Recs in ABR | 12 |
Average Target Price | $25.55 |
LT Growth Rate | 3.80% |
Industry | Medical - Products |
Industry Rank by ABR | 150 of 252 |
Current Quarter EPS Est: | 0.32 |